tirzepatide weight loss nejm In the SURMOUNT-1 trial (published in in July 2022), adults with #obesity treated with weekly tirzepatide, a glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptor Tirzepatide Once Weekly for the

They observed a body weight loss difference of 2.9 kg between tirzepatide and GLP-1 RAs, although the specific GLP-1 RA was not identified, limiting direct comparison with our study

The weakest part of the argument is that no clinical trial has ever tested this specific combination, the additive effect of levocarnitine on top of tirzepatide substantial metabolic impact may be negligible, and the cost premium is not clearly justified by the expected benefit

We offer a range of complementary and alternative therapies that can help improve overall health and well-being

Our cover insurance verification, prior authorization, pharmacy support, and more, allowing you to stay focused on achieving your health ambitions

J., Saluja, S., & Francis, H